Table 1.
Baseline patient characteristics.
Fig 1.
Flow sheet summarizing study selection.
Table 2.
Factors associated with early recurrence of HCC within six months of completing antiviral therapy.
Table 3.
AUROC for items for which cutoff values were set in Table 2.
Table 4.
Factors associated with early recurrence of HCC within six months of completing antiviral therapy in patients who achieved SVR.
Table 5.
AUROC for items for which cutoff values were set in Table 4.
Table 6.
Factors associated with recurrence of HCC after completing antiviral therapy in patients who achieved SVR.
Table 7.
AUROC for items for which cutoff values were set in Table 6.
Table 8.
Patient characteristics after propensity score matching.
Fig 2.
Cumulative hepatocellular carcinoma (HCC) recurrence rate in patients who achieved sustained virological response.
Kaplan-Meier analysis does not show a significant difference between the IFN group (gray line) and IFN-free DAA group (black line).
Fig 3.
HCC cumulative recurrence rate after propensity score matching.
Kaplan-Meier analysis performed after matching also revealed no significant difference between the IFN group (gray line) and the IFN-free DAA group (black line).